Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.
The rates of resistance to erythromycin and clindamycin among Streptococcus agalactiae strains isolated in our hospital increased from 4.2 and 0.8% in 1993 to 17.4 and 12.1%, respectively, in 2001. Erythromycin resistance was mainly due to the presence of an Erm(B) methylase, while the M phenotype was detected in 3.8% of the strains. Telithromycin was very active against erythromycin-resistant strains, irrespective of their mechanisms of macrolide resistance.
Betriu
C
C
Department of Clinical Microbiology, Hospital Clínico San Carlos, 28040 Madrid, Spain. cbetriu@efd.net
Culebras
E
E
Gómez
M
M
Rodríguez-Avial
I
I
Sánchez
B A
BA
Agreda
M C
MC
Picazo
J J
JJ
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D007231:Infant, Newborn; D048628:Ketolides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D013030:Spain / Q000453:epidemiology; D013290:Streptococcal Infections / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D013292:Streptococcus agalactiae / Q000187:drug effects*; D013753:Tetracycline Resistance
D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; D002981:Clindamycin; D004917:Erythromycin; C106791:telithromycin